205 related articles for article (PubMed ID: 23469976)
41. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
[TBL] [Abstract][Full Text] [Related]
42. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion.
Taiyab A; Rao ChM
Biochim Biophys Acta; 2011 Jan; 1813(1):213-21. PubMed ID: 20883729
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
44. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
45. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
Johnson AJ; Wagner AJ; Cheney CM; Smith LL; Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC
Br J Haematol; 2007 Dec; 139(5):837-44. PubMed ID: 17949452
[TBL] [Abstract][Full Text] [Related]
46. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
[TBL] [Abstract][Full Text] [Related]
47. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.
Watanabe G; Behrns KE; Kim JS; Kim RD
Cancer Chemother Pharmacol; 2009 Aug; 64(3):433-43. PubMed ID: 19082595
[TBL] [Abstract][Full Text] [Related]
48. 15-lipoxygenase-1/15-hydroxyeicosatetraenoic acid promotes hepatocellular cancer cells growth through protein kinase B and heat shock protein 90 complex activation.
Ma J; Zhang L; Zhang J; Liu M; Wei L; Shen T; Ma C; Wang Y; Chen Y; Zhu D
Int J Biochem Cell Biol; 2013 Jun; 45(6):1031-41. PubMed ID: 23474367
[TBL] [Abstract][Full Text] [Related]
49. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
50. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
[TBL] [Abstract][Full Text] [Related]
51. High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin.
Lukasiewicz E; Miekus K; Kijowski J; Gozdzik J; Wilusz M; Bobis-Wozowicz S; Wiecha O; Majka M
J Physiol Pharmacol; 2009 Sep; 60(3):161-6. PubMed ID: 19826195
[TBL] [Abstract][Full Text] [Related]
52. Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition.
Huang Z; Zhou X; He Y; Ke X; Wen Y; Zou F; Chen X
Sci Rep; 2016 Dec; 6():38072. PubMed ID: 27909289
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of heat shock protein 90 attenuates post‑angioplasty intimal hyperplasia.
Kassem MM; Muqri F; Dacosta M; Bruch D; Gahtan V; Maier KG
Mol Med Rep; 2020 Apr; 21(4):1959-1964. PubMed ID: 32319637
[TBL] [Abstract][Full Text] [Related]
54. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
55. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
[TBL] [Abstract][Full Text] [Related]
56. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
Myung SJ; Yoon JH; Kim BH; Lee JH; Jung EU; Lee HS
J Pharmacol Exp Ther; 2009 Jul; 330(1):276-82. PubMed ID: 19329756
[TBL] [Abstract][Full Text] [Related]
57. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
Newcomb EW; Lukyanov Y; Schnee T; Esencay M; Fischer I; Hong D; Shao Y; Zagzag D
Anticancer Drugs; 2007 Sep; 18(8):875-82. PubMed ID: 17667592
[TBL] [Abstract][Full Text] [Related]
58. Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas.
Singh A; Singh A; Sand JM; Bauer SJ; Hafeez BB; Meske L; Verma AK
J Invest Dermatol; 2015 Apr; 135(4):1098-1107. PubMed ID: 25337691
[TBL] [Abstract][Full Text] [Related]
59. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death.
Pritchard JR; Cosgrove BD; Hemann MT; Griffith LG; Wands JR; Lauffenburger DA
Mol Cancer Ther; 2009 Aug; 8(8):2183-92. PubMed ID: 19671754
[TBL] [Abstract][Full Text] [Related]
60. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
Walker T; Mitchell C; Park MA; Yacoub A; Rahmani M; Häussinger D; Reinehr R; Voelkel-Johnson C; Fisher PB; Grant S; Dent P
Mol Cancer Ther; 2010 May; 9(5):1378-95. PubMed ID: 20442308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
